43 research outputs found
μνμ κ²½λ§ κΈ°λ° λΉμ ν ARMA-GARCH λͺ¨νμ μ΄μ©ν S&P500 μ§μ μμΈ‘
νμλ
Όλ¬Έ(μμ¬)--μμΈλνκ΅ λνμ :μμ°κ³Όνλν ν΅κ³νκ³Ό,2019. 8. μ΄μμ΄.A nonlinear ARMA-GARCH model is proposed for forecasting daily stock market returns. The only difference from the linear ARMA-GARCH is the conditional mean component. Two parameters are added and the hyperbolic tangent function is utilized to give a nonlinearity. The nonlinear ARMA-GARCH is solved by the recurrent neural network concept. In order to show the practical applicability of the proposed nonlinear ARMA-GARCH model, daily algorithmic trading is carried out with historical S&P500 daily closing index from 1950 to 2018. It is shown that the proposed nonlinear ARMA-GARCH model outperforms the linear ARMA-GARCH model in terms of financial and statistical measures.μΌλ³ μ£Όκ° μμΈ‘μ μν μνμ κ²½λ§ κΈ°λ° λΉμ ν ARMA-GARCH λͺ¨νμ΄ μ μλμλ€. κΈ°λ³Έμ μΈ μ ν ARMA-GARCH λͺ¨νμ λ κ°μ λͺ¨μκ° λν΄μ§κ³ μ곑νμ νΈν¨μλ₯Ό μ΄μ©νμ¬ λΉμ νμ±μ΄ μΆκ°λ λͺ¨νμ΄λ€. μ μλ λΉμ ν ARMA-GARCH λͺ¨νμ ν΄λ μνμ κ²½λ§ κ°λ
μ μ΄μ©νμ¬ μ»μλ€. μ μλ λͺ¨νμ νμ€μ μ μ© κ°λ₯μ±μ 보μ΄κΈ° μνμ¬ 1950λ
λΆν° 2018λ
κΉμ§ S&P500 μ§μμ μΌλ³ μ’
κ°λ₯Ό μ΄μ©νμ¬ μκ³ λ¦¬μ¦ κΈ°λ° κ±°λλ₯Ό μννμλ€. κΈμ΅ λ° ν΅κ³μ μΈ‘λλ‘ λΉκ΅νμμ λ μ μλ λΉμ ν ARMA-GARCH λͺ¨νμ΄ κΈ°μ‘΄μ μ ν ARMA-GARCH λͺ¨νλ³΄λ€ λ°μ΄λ¨μ 보μλ€.Abstract i
List of Figures iii
List of Tables iv
Chapter 1 Introduction 1
Chapter 2 Data Description 3
Chapter 3 Model Description 6
3.1 Nonlinear ARMA-GARCH Model 7
3.2 Recurrent Neural Networks Structure 8
3.3 Model Selection 10
3.4 Trading Strategies 12
Chapter 4 Results 13
Chapter 5 Concluding Remarks 17
Bibliography 18
κ΅λ¬Έμ΄λ‘ 22Maste
Clinical outcomes of hepatitis B virus infection are not associated with Fas and FasL gene polymorphisms
Thesis(master`s)--μμΈλνκ΅ λνμ :μνκ³Ό λΆμμ μ 체μνμ 곡,2006.Maste
Transmission electron microscopic and immunohistochemical study of transverse carpal ligaments in patients with carpal tunnel syndrome
νμλ
Όλ¬Έ(λ°μ¬)--μμΈλνκ΅ λνμ :μνκ³Ό μ νμΈκ³Όνμ 곡,2001.Docto
λ§μΌν μμ€ν κ³Ό ιδΏε ζ°η₯μ ι©εζ§μ κ΄ν η‘η©Ά
νμλ
Όλ¬Έ(μμ¬)--μμΈε€§εΈζ ‘ 倧εΈι’ :ηΆηεΈη§ ηΆηεΈε°ζ»,1996.Maste
Interaction between HBV replication and miR-17-92 expression in human hepatoma cells
MicroRNAs (miRNAs) regulate post-transcriptional gene expression in various physiologic and pathologic biological processes. The miR-17-92 cluster encodes six miRNAs (miR-17, miR-18a, miR-19a, miR-19b, miR-20a, and miR-92-1) which are transactivated by c-Myc. Previous studies reported that hepatitis B virus (HBV), the main cause of chronic viral hepatitis in Korea, transactivates c-Myc. The purposes of this study were to examine the effect of HBV replication on the miR-17-92 expression, and to determine whether miR-17-92 regulates HBV replication. The expression of miR-17-92 was examined in HepAD38 cells that permit conditional replication of HBV by real-time quantitative PCR and Northern blot analysis. HBV relaxed circular DNA and pregenomic RNA levels were quantified in HepAD38 cells that were transfected with either miR-17-92 expression plasmids or antisense peptide nucleic acids against miR-17-92. Induction of HBV replication up-regulated transcription of miR-17-92 in HepAD38 cells. Moreover, miR-20a was up-regulated in liver tissues from chronic hepatitis B patients compared to control liver tissues without active HBV infection. Induction of HBV replication up-regulated c-Myc expression in HepAD38 cells, and HBV-induced overexpression of miR-17-92 was reversed by lentivirus-mediated RNA interference of c-Myc. Overexpression of miR-17-92 did not influence HBV replication significantly, whereas antisense peptide nucleic acids against miR-17-92 augmented HBV replication. Luciferase reporter assays confirmed direct interaction between miR-17-92 and potential target sequences on the HBV genome. These results demonstrate that HBV up-regulates miR-17-92 expression via c-Myc, and in turn, the miR-17-92 polycistron restricts replication of HBV in HepAD38 cells. These novel findings suggest negative feedback regulation of HBV by the miR-17-92 cluster.λ§μ΄ν¬λ‘ RNAs (miRNAs)λ λ¨μΌκ°λ₯μ RNA λΆμλ‘μ λ©μ μ RNA (mRNA)μ μΌκΈ°μμ μ΄λ£¨λ©΄μ μ μ¬ νμ μ§ν΅ μλ¬Όμ μ μ μλ°νμ μ μ΄νλ μλ‘μ΄ μ‘°μ λ¬Όμ§λ‘ μΈν¬ μ¦μ, λΆν, μΈν¬ μ¬λ©Έ, μν κ³Όμ μ κ΄μ¬νλ κ²μΌλ‘ μλ €μ Έ μλ€. MiR-17-92 ν΄λ¬μ€ν°λ 6κ°μ miRNA (miR-17, miR-18a, miR-19a, miR-19b, miR-20a, and miR-92-1) λ°ννλ λνμ μΈ μκ΄λ ¨ miRNAλ‘ κ°μΈν¬μμ ν¬ν¨ν μ¬λ¬ μ μμ κ·Έ μν μ΄ μ‘°λͺ
μ λ°μ μλ€. νΉν κ°μΈν¬μμμλ c-Myc μ μ μμ μν μ μ¬μ΄μ§ (transactivation) μ μν΄ miR-17-92μ΄ κ³Όλ°νλ¨μ΄ λ°νμ‘λ€. μ΄ μ°κ΅¬μ λͺ©μ μ miR-17-92μ Bν κ°μΌ λ°μ΄λ¬μ€ (Hepatitis B virus, HBV)μ μνΈμμ© λ° λ§€κ°μλ‘μμ c-Mycμ μ μμ μν μ νμΈνλ κ²μ΄λ€.
HBVμ μ¦μμ΄ miR-17-92μ λ―ΈμΉλ μν₯μ νμΈνκΈ° μν΄μ HepAD38 κ°μμΈν¬μ£Όλ₯Ό μ¬μ©νμμΌλ©°, c-Mycμ μν μ νμΈνκΈ° μν΄μ λ ν°λ°μ΄λ¬μ€λ₯Ό μ΄μ©ν short-hairpin RNA λ§€κ° knockdown λ°©λ²μ μ΄μ©νμλ€. λν HepAD38 μΈν¬μ£Όμμ miR-17-92λ₯Ό κ³Όλ°ν λλ μ΅μ λ₯Ό μμΌ μΈν¬λ΄ HBV μ¦μμ λ―ΈμΉλ μν₯μ νμΈνμλ€.
HBVλ miR-17-92μ μ μ¬λ₯Ό μ΄μ§ν¨μ νμΈνμμΌλ©°, μ΄λ c-Mycμ μν΄μ 맀κ°λ¨μ λ°ν μ μμλ€. ννΈ miRNA λ°ν νλΌμ¦ λ―Έλλ₯Ό μ΄μ©νμ¬ miR-17-92λ₯Ό κ³Όλ°ν μμΌ°μ λ HBVμ μ¦μμ λ³νλ μμμΌλ peptide nucleic acidλ₯Ό μ΄μ©νμ¬ miR-17-92μ μ΅μ μμΌ°μ λ HBVμ μ¦μμ΄ νμ§λ¨μ νμΈνμλ€. Luciferase reporter analysisλ₯Ό ν΅νμ¬ miR-17-92μ΄ HBVμ μ μ¬μ²΄μ μ§μ μμ©ν¨μ νμΈ νμλ€.
λ³Έ μ°κ΅¬λ₯Ό ν΅νμ¬ miR-17-92μ HBVμ μνΈμμ©μ νμΈνμμΌλ©° miR-17-92κ° HBVμ μμ°κ²½κ³Ό λ° κ°μΈν¬μκ³Ό κ΄λ ¨λ λ³νμ리νμ κΈ°μ μ κ΄μ¬ν μ μμμ 보μ¬μ£Όμλ€.Docto